Literature DB >> 8387566

Long-term survival in malignant glioma. Prognostic factors.

S Phuphanich1, S Ferrall, H Greenberg.   

Abstract

Mean survival of patients with malignant glioma is six months. Only 7.5% of these patients survive two years. We identified 14 patients, nine with glioblastoma multiforme and five with anaplastic astrocytoma, who survived more than two years. All were treated initially with surgery, radiation and adjuvant chemotherapy. One patient who received three years of nitrosourea has lived longer than 7.3 years. Seven of the 14 patients have no sign of tumor recurrence four years after diagnosis. Nine surviving patients were younger than 45 years of age at the time of diagnosis. Five died of tumor recurrence with the median survival time of 3.5 years. This data suggests that onset at a younger age (< 45 years), multimodality therapy, high Karnofsky Performance Scale and frontal lobe tumors were the major prognostic factors that contributed to long-term survival.

Entities:  

Mesh:

Year:  1993        PMID: 8387566

Source DB:  PubMed          Journal:  J Fla Med Assoc        ISSN: 0015-4148


  12 in total

1.  Brain tumor survival: results from the National Cancer Data Base.

Authors:  T S Surawicz; F Davis; S Freels; E R Laws; H R Menck
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

2.  The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue.

Authors:  D D Martin; M E Robbins; A A Spector; B C Wen; D H Hussey
Journal:  Lipids       Date:  1996-12       Impact factor: 1.880

3.  Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill.

Authors:  S Vartak; M E Robbins; A A Spector
Journal:  Lipids       Date:  1997-03       Impact factor: 1.880

Review 4.  Patients' Survival with Astrocytoma After Treatment: a Systematic Review and Meta-analysis of Clinical Trial Studies.

Authors:  Nader Salari; Reza Fatahian; Mohsen Kazeminia; Amin Hosseinian-Far; Shamarina Shohaimi; Masoud Mohammadi
Journal:  Indian J Surg Oncol       Date:  2022-04-25

5.  Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice?

Authors:  Fadime Akman; Rachel A Cooper; Mehmet Sen; Yildiray Tanriver; Süleyman Kentli
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

6.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.

Authors:  M Morita; M K Rosenblum; M H Bilsky; R A Fraser; M R Rosenfeld
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

7.  Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma.

Authors:  Gerald N DeLorenze; Lucie McCoy; Ai-Lin Tsai; Charles P Quesenberry; Terri Rice; Dora Il'yasova; Margaret Wrensch
Journal:  BMC Cancer       Date:  2010-05-19       Impact factor: 4.430

8.  Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.

Authors:  Stella M Ranuncolo; Mirta Varela; Ana Morandi; José Lastiri; Silvia Christiansen; Elisa Bal de Kier Joffé; María G Pallotta; Lydia Puricelli
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

9.  Long-term survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: a case report and review of the literature.

Authors:  Sudheer R Thumma; Ameer L Elaimy; Nathan Daines; Alexander R Mackay; Wayne T Lamoreaux; Robert K Fairbanks; John J Demakas; Barton S Cooke; Christopher M Lee
Journal:  Case Rep Med       Date:  2012-04-04

10.  Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme.

Authors:  Eleftherios Archavlis; Nikolaos Tselis; Gerhard Birn; Peter Ulrich; Dimos Baltas; Nikolaos Zamboglou
Journal:  BMJ Open       Date:  2013-03-15       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.